

FIRST LIGHT

RESEARCH

Top picks

Mid-cap ideas

Laurus Labs replaced by **Ajanta Pharma**
 (see [Another good quarter, 3May21](#))

[#4 Meeting of Minds] Automobiles

Transforming India into a global cell manufacturing hub

BOB Economics Research | Weekly Wrap

India's second wave plateauing

Power

Regulators want lower ROE – NTPC, PWGR most at risk

SUMMARY

Automobiles

We hosted Kowtham Raj VS, an active member of government think tank NITI Aayog who plays a key advisory role in India's battery/solar manufacturing and hydrogen schemes. The central government has introduced a Rs 180bn programme to kickstart large-scale local manufacturing of ACC batteries. Kowtham expects India to become a preferred destination for cell manufacturing and to have its first gigafactory in 2-3 years. He also believes the complexities of this technology could spur JVs between domestic OEMs and global battery makers.

[Click here for the full report.](#)

TOP PICKS

LARGE-CAP IDEAS

Company	Rating	Target
TCS	Buy	3,780
Tech Mahindra	Buy	1,190
Tata Power	Buy	131

MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	3,750
Ajanta Pharma	Buy	2,300
Alembic Pharma	Buy	1,230

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.62	0bps	8bps	95bps
India 10Y yield (%)	5.98	1bps	(7bps)	20bps
USD/INR	72.84	0.4	2.8	3.7
Brent Crude (US\$/bbl)	66.44	2.0	1.6	84.2
Dow	34,208	0.4	1.2	39.8
Shanghai	3,487	(0.6)	0.6	21.6
Sensex	50,540	2.0	5.1	63.4
India FII (US\$ mn)	20 May	MTD	CYTD	FYTD
FII-D	14.4	301.3	(2,091.1)	(63.8)
FII-E	30.6	(432.2)	5,405.0	(1,921.3)

Source: Bank of Baroda Economics Research

BOBCAPS Research

researchreport@bobcaps.in



India Economics: Weekly Wrap

Global yields fell on the back of dip in US housing starts and lower than expected retail sales and industrial output from China. DXY index was weak. On the domestic front, our weekly economic tracker shows economic activity has slowed down further to 79 from 81. Activity should improve next month with cases peaking. Equity markets rose on the back of reduction in cases. India's Q4FY21 GDP data will be released this week along with Centre's FY21 fiscal data. We expect GDP growth at 9.7% in FY22 from (-) 7.7% in FY21.

[Click here for the full report.](#)

Power

As per the Economic Times, the Forum of Regulators – a body comprising CERC and state regulators – has released a report making recommendations to reduce electricity tariffs for end users. Key recommendations: (1) reduce regulated ROE for generators as well as transmission and distribution companies, (2) link generation and transmission ROE with the average five-year G-Sec yield plus a risk premium, (3) permit State Regulatory Commissions to decide distribution ROE but limit tax pass-through to the ROE component. We do not see any immediate risk as the next CERC review that will set the tone for state regulators will be effective only from Apr'24.

[Click here for the full report.](#)

Transforming India into a global cell manufacturing hub

We hosted Kowtham Raj VS, an active member of government think tank NITI Aayog who plays a key advisory role in India's battery/solar manufacturing and hydrogen schemes. The central government has introduced a Rs 180bn programme to kickstart large-scale local manufacturing of ACC batteries. Kowtham expects India to become a preferred destination for cell manufacturing and to have its first gigafactory in 2-3 years. He also believes the complexities of this technology could spur JVs between domestic OEMs and global battery makers.

Mayur Milak | Nishant Chowhan, CFA
 researchreport@bobcaps.in

Gigafactory programme to address local battery manufacturing: NITI Aayog has set up a National Programme on Advanced Chemistry Cell (ACC) Battery manufacturing, aka India's battery "gigafactory" scheme. The programme is designed to incentivise companies that intend to set up gigafactories in India primarily to address electric mobility and energy storage for renewables and electronics.

Incentives up to Rs 180bn on offer for large-scale production: The central government is offering strong incentives to any company that intends to set up between 5GWh and 20GWh of cell manufacturing capacity in India. The initial investment for such a setup is pegged at ~Rs 5bn/GWh. Incentives on units sold are designed only for larger players to scale up, with the idea of kickstarting the industry. Kowtham explained that the base incentive is 20% of sales value provided the localisation is 100% or a 10% benefit for ~50% localisation.

JVs likely between domestic OEMs and global battery manufacturers: Cell manufacturing could be a highly advanced technological process, including domestic setup of the entire supply chain for anodes, cathodes and separators. Given these complexities, India could witness a joint venture model between domestic OEMs and global battery manufacturers, as seen around the globe. Even leaders such as LG and Samsung prefer JVs. Tesla depends on Panasonic for its battery requirements.

Priming India to become a preferred battery manufacturing hub: The battery industry typically earns 12-15% operating margins. Kowtham believes that even with a 10% cash incentive on sales, battery manufacturing could become the cheapest in the world, thus making India a preferred destination not only for self-consumption but also for global exports.

Meeting of Minds

– An Expert Perspective

This is the fourth in our 'Meeting of Minds' series where we host experts and leaders in various fields to discuss key events and trends in the Auto and Aviation sectors.

REPORTS IN THIS SERIES

SN	Title
#1	Auto: Rubber prices headed for a structural bull run
#2	Aviation: Time for airline fleet consolidation; near-term pain to persist
#3	Automobiles: Gearing up for EV battery technology



WEEKLY WRAP

24 May 2021

India's second wave plateauing

Global yields fell on the back of dip in US housing starts and lower than expected retail sales and industrial output from China. DXY index was weak. On the domestic front, our weekly economic tracker shows economic activity has slowed down further to 79 from 81. Activity should improve next month with cases peaking. Equity markets rose on the back of reduction in cases. India's Q4FY21 GDP data will be released this week along with Centre's FY21 fiscal data. We expect GDP growth at 9.7% in FY22 from (-) 7.7% in FY21.

Sameer Narang | Jahnavi

chief.economist@bankofbaroda.com

Markets

- **Bonds:** Global yields broadly closed lower led by China's 10Y yield which fell by 6bps (3.07%) on the back of muted retail sales and industrial production. US 10Y yield fell by 1bps (1.62%) despite FOMC hinting at adjustment to its asset purchase program. Crude prices fell by 3.3% (US\$ 66/bbl) amidst fear of muted demand. India's 10Y yield fell by 1bps (5.98%). System liquidity surplus fell to Rs 3.7tn as on 21 May 2020 from Rs 4.2tn in previous week.
- **Currency:** Except AUD (lower) and CNY (flat), other global currencies closed higher this week. DXY fell by 0.3% amidst expectations that Fed will continue to remain dovish. EUR gained 0.3% as Eurozone's services PMI rose sharply in May'21. INR rose by 0.6% to a 2-month high supported by lower oil prices and FII inflows (US\$ 395mn).
- **Equity:** Global indices ended mixed. Weak US housing starts and subdued data from China drove these two markets lower. Sensex (3.7%) rose the most led by drop in infections in India. Banking and oil and gas stocks rose.
- **Covid-19 tracker:** Global Covid-19 cases rose by 4.2mn this week lower than 4.8mn last week. In India as well, cases rose at a slower pace of 1.8mn versus 2.4mn, WoW. Our weekly economic activity tracker index dipped to 79 (100=Feb'20) from 81 in last week. Israel has vaccinated 63% of its population (single dose) and US at 49%. India is now at 11%.
- **Upcoming key events:** US and German GDP and consumer confidence data will be released along with rate decision of BoK. In India, progress in vaccination, Covid-19 cases, GDP and fiscal data will be keenly seen.



POWER

24 May 2021

Regulators want lower ROE – NTPC, PWGR most at risk

Forum of Regulators' recommendations: As per the Economic Times, the Forum of Regulators – a body comprising CERC and state regulators – has released a report making recommendations to reduce electricity tariffs for end users. Key recommendations as per the [report on the forum's website](#):

- Reduce regulated ROE for generators as well as transmission and distribution companies
- Link generation and transmission ROE with the average five-year G-Sec yield plus a risk premium (ROE currently at 15.5% till FY24)
- Permit State Regulatory Commissions to decide distribution ROE but limit tax pass-through to the ROE component – implying taxes on incentives related to lower AT&C losses and recoveries would not be passed through
- Shorten the tenure of PPAs and remove bulk power supply agreements (BPSA) which obligate discoms to exit all PPAs older than 25 years in the region if they want to exit just one uneconomical agreement
- Award state transmission projects above a certain value via competitive bids
- Encourage renewable-led distributed generation systems, hybrid or round-the-clock (RTC) projects for better utilisation of transmission assets

No immediate risk: We do not see any immediate risk as the next CERC review that will set the tone for state regulators and impact companies such as NTPC and Power Grid (PWGR) will be effective only from Apr'24.

NTPC and PWGR have largest exposure to regulated business: Regulated business contribution to NTPC and PWGR's EBITDA is well over 90%. This is ~50% for Torrent Power (TPW)) and CESC, and ~40% for Tata Power (TPWR). A 1.5% reduction in ROE would result in a 10% drop in net income for NTPC and PWGR, all else remaining the same. For TPWR, TPW and CESC, the impact could be limited to ~5%.

TPWR our top pick: TPWR (TP: Rs 131, BUY) is our top pick – for details see our recent initiation report, [Power: Cleaning up its act](#). Stock catalysts include the announcement of new external investments into the renewable business, disinvestment of non-core assets, and group restructuring to save costs.

Tarun Bhatnagar


researchreport@bobcaps.in

KEY RECOMMENDATIONS

Ticker	Price	Target	Rating
TPWR IN	105	131	BUY
PWGR IN	227	261	ADD
TPW IN	435	461	ADD
CESC IN	689	721	ADD
NTPC IN	113	111	REDUCE

Price & Target in Rupees | Price as of 21 May 2021

FY22E EBITDA mix



Source: Company, BOBCAPS Research



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Rating distribution

As of 30 April 2021, out of 90 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 16 have ADD ratings, 5 are rated REDUCE and 26 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such.

Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.